Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2 publications
FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 18, 2018
First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 27, 2013
Showing 1-2 of 2
Last Updated: 09/26/2026